JP2004500325A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004500325A5 JP2004500325A5 JP2000617923A JP2000617923A JP2004500325A5 JP 2004500325 A5 JP2004500325 A5 JP 2004500325A5 JP 2000617923 A JP2000617923 A JP 2000617923A JP 2000617923 A JP2000617923 A JP 2000617923A JP 2004500325 A5 JP2004500325 A5 JP 2004500325A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antagonist
- receptor
- binds
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000013691 Interleukin-17 Human genes 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 102000004554 Interleukin-17 Receptors Human genes 0.000 description 6
- 108010017525 Interleukin-17 Receptors Proteins 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99401191A EP1053751A1 (en) | 1999-05-17 | 1999-05-17 | Compositions and methods for treating cell proliferation disorders |
| PCT/US2000/008081 WO2000069463A1 (en) | 1999-05-17 | 2000-03-27 | Compositions and methods for treating cell proliferation disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004500325A JP2004500325A (ja) | 2004-01-08 |
| JP2004500325A5 true JP2004500325A5 (enExample) | 2007-05-24 |
Family
ID=8241974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000617923A Pending JP2004500325A (ja) | 1999-05-17 | 2000-03-27 | 細胞増殖障害を処置するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP1053751A1 (enExample) |
| JP (1) | JP2004500325A (enExample) |
| AU (1) | AU4033900A (enExample) |
| CA (1) | CA2373938A1 (enExample) |
| MX (1) | MXPA01011923A (enExample) |
| WO (1) | WO2000069463A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005010044A2 (en) | 2003-07-08 | 2005-02-03 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
| PT1537878E (pt) * | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| CN101374864A (zh) * | 2006-01-31 | 2009-02-25 | 诺瓦提斯公司 | 用于靶向癌症的il-17拮抗性抗体 |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| EP2569335B1 (en) * | 2010-05-14 | 2018-08-22 | Orega Biotech | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists |
| ME02734B (me) | 2011-01-14 | 2017-10-20 | Ucb Biopharma Sprl | Antitelo koje vezuje il-17a i il-17f |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| EP3164113B1 (en) | 2014-06-04 | 2019-03-27 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| JP7186094B2 (ja) | 2016-05-06 | 2022-12-08 | イグジキュア オペレーティング カンパニー | インターロイキン１７受容体ｍＲＮＡの特異的ノックダウンのためのアンチセンスオリゴヌクレオチド（ＡＳＯ）を提示するリポソーム系球状核酸（ＳＮＡ）構築物 |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| EP4087858A1 (en) * | 2020-01-10 | 2022-11-16 | Carogen Corporation | Compositions and methods of use of oncolytic virus like vesicles |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU727480B2 (en) * | 1995-07-19 | 2000-12-14 | Genetics Institute, Llc | Human CTLA-8 and uses of CTLA-8-related proteins |
| ATE442385T1 (de) * | 1997-09-17 | 2009-09-15 | Human Genome Sciences Inc | Interleukin-17 rezeptor-ähnliches protein |
| DE29820466U1 (de) * | 1998-11-16 | 1999-04-08 | Reutter, Werner, Prof. Dr.med., 14195 Berlin | Rekombinante Glycoproteine und sie enthaltende Arzneimittel |
-
1999
- 1999-05-17 EP EP99401191A patent/EP1053751A1/en not_active Withdrawn
-
2000
- 2000-03-27 CA CA002373938A patent/CA2373938A1/en not_active Abandoned
- 2000-03-27 AU AU40339/00A patent/AU4033900A/en not_active Abandoned
- 2000-03-27 WO PCT/US2000/008081 patent/WO2000069463A1/en not_active Ceased
- 2000-03-27 MX MXPA01011923A patent/MXPA01011923A/es not_active Application Discontinuation
- 2000-03-27 EP EP00919693A patent/EP1251872A1/en not_active Withdrawn
- 2000-03-27 JP JP2000617923A patent/JP2004500325A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU8867501A (en) | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design | |
| WO2002028481A3 (en) | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies | |
| HUP0301465A3 (en) | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition | |
| EP1178786A4 (en) | PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE | |
| JP2002519434A5 (enExample) | ||
| WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| TR200100172T2 (tr) | Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar | |
| ATE376832T1 (de) | Verzögert freisetzende formulierungen von oxymorphon | |
| AU9399501A (en) | Therapeutic antibodies | |
| EE05309B1 (et) | β-Amloidpeptiidi ratundvad humaniseeritud antikehad, meetod nende valmistamiseks, nende kasutamine ja farmatseutiline kompositsioon | |
| DE60130256D1 (de) | Naphthalinderivate, die sich an den ep4?rezeptor binden | |
| WO2004056337A3 (en) | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats | |
| AU2001263229A1 (en) | Compositions and methods for administration of pharmacologically active compounds | |
| WO2002047715A3 (en) | Compositions of peptide crystals | |
| MA27265A1 (fr) | Formulations d'agoniste opioide a antagoniste liberable et sequestre | |
| WO2002032375A8 (en) | Uses of monoclonal antibody 8h9 | |
| HUP0401805A2 (hu) | Pulmonális betegségek kezelésére szolgáló vegyületek | |
| TR200103432T2 (tr) | Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı. | |
| ATE457318T1 (de) | Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper | |
| NO20013459D0 (no) | Anvendelse av agiotensin II reseptorantagonister ved behandling av akutt myokardinfarkt | |
| AU2001255537A1 (en) | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs | |
| AU1712700A (en) | Restoration of platelet aggregation by antibody administration after gpiib/iiia antagonist treatment | |
| MXPA02012015A (es) | Ligandos de receptores para integrinas. | |
| JP2001518516A5 (enExample) | ||
| JP2002514404A5 (enExample) |